Medical Update: Byline Corrections Issued for Landmark Patent Ductus Arteriosus in Preterm Infants Trial
In a recent administrative correction to one of the most anticipated studies in neonatal cardiology, officials have updated the authorship of the “Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: the PDA Randomized Clinical Trial.”
The correction, issued for the Feb. 17, 2026, publication, clarifies the primary contributions of the research team. Praveen K. Chandrasekharan, MD, MS, has been formally added to the byline, replacing Anne Marie Reynolds, MD, MPH.
Dr. Reynolds, whose contributions remain vital to the study’s success, has been moved to the “Additional Contributions” section to better reflect the project’s internal roles. The article has been corrected across all online platforms to maintain the integrity of the academic record.
While the change is administrative, it underscores the rigorous standards of transparency required in clinical trials that shape the future of neonatal care. Does the precision of author attribution impact the perceived reliability of medical data? Or is this simply a routine bureaucratic adjustment in the world of high-stakes research?
Understanding Patent Ductus Arteriosus in Preterm Infants
To understand why this trial is so significant, one must first understand the condition it addresses. Patent Ductus Arteriosus (PDA) is a common challenge in the Neonatal Intensive Care Unit (NICU).
In a developing fetus, the ductus arteriosus is a blood vessel that allows blood to bypass the lungs, which are not yet functioning. Normally, this vessel closes shortly after birth.
However, in preterm infants, this closure often fails to occur. When the vessel remains “patent” (open), it can lead to an overload of blood flowing into the lungs, potentially causing respiratory distress and straining the heart.
The Great Debate: Watchful Waiting vs. Medical Intervention
For years, neonatologists have been divided on the best course of action. On one side is expectant management—a “watch and wait” approach where clinicians monitor the infant, allowing the PDA to close on its own over time.
On the other side is pharmacological intervention. This typically involves the use of medications such as indomethacin or ibuprofen, which are designed to constrict the vessel and force closure.
The tension between these two methods lies in the risk-benefit ratio. While medication can close a PDA faster, it may carry risks of kidney impairment or bowel complications. Conversely, expectant management may leave the infant vulnerable to lung congestion for a longer period.
How do we balance the immediate need for closure against the long-term risks of medication? This is the central question that the PDA Randomized Clinical Trial seeks to answer by providing evidence-based data on patient outcomes.
For those seeking deeper clinical insights, the National Center for Biotechnology Information (NCBI) offers extensive databases on neonatal hemodynamic stability. Additionally, the American Academy of Pediatrics (AAP) provides guidelines on the standard of care for premature births.
The updated trial findings serve as a cornerstone for clinicians worldwide, ensuring that the care provided to the most vulnerable patients is backed by accurate, peer-reviewed research and properly credited expertise.
Frequently Asked Questions About PDA in Preterm Infants
- What is Patent Ductus Arteriosus in preterm infants?
- It is a condition where a fetal blood vessel fails to close after birth, causing abnormal blood flow between the aorta and the pulmonary artery.
- What is expectant management for Patent Ductus Arteriosus in preterm infants?
- It is a conservative strategy where doctors monitor the infant without using medication, allowing the ductus to close naturally.
- How is medication used to treat Patent Ductus Arteriosus in preterm infants?
- Doctors typically administer NSAIDs, such as ibuprofen or indomethacin, to trigger the closure of the vessel.
- Why was the PDA Randomized Clinical Trial updated?
- The update was necessary to correct the byline, ensuring Dr. Praveen K. Chandrasekharan was credited as a primary author and Dr. Anne Marie Reynolds was moved to additional contributions.
- What are the risks of Patent Ductus Arteriosus in preterm infants?
- Potential risks include pulmonary hypertension, increased oxygen requirements, and a higher risk of necrotizing enterocolitis (NEC).
Medical Disclaimer: The information provided in this article is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Was this update helpful? Share this article with your colleagues and join the conversation in the comments below to discuss the evolving standards of neonatal care.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
